Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 6;121(23):4778-81.
doi: 10.1182/blood-2013-01-478891. Epub 2013 Apr 16.

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

Giovanni Barosi  1 , Ruben Mesa, Guido Finazzi, Claire Harrison, Jean-Jacques Kiladjian, Eva Lengfelder, Mary F McMullin, Francesco Passamonti, Alessandro M Vannucchi, Carlos Besses, Heinz Gisslinger, Jan Samuelsson, Srdan Verstovsek, Ronald Hoffman, Animesh Pardanani, Francisco Cervantes, Ayalew Tefferi, Tiziano Barbui
Affiliations

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

Giovanni Barosi et al. Blood. .

Abstract

Standardized response criteria to interpret and compare clinical trials are needed for approval of new therapeutic agents by regulatory agencies. The European LeukemiaNet (ELN) response criteria for essential thrombocythemia (ET) and polycythemia vera (PV) issued in 2009 have been widely adopted as end points in a number of recent clinical trials. However, evidence exists that they do not predict response or provide clinically relevant measures of benefit for the patients. This article presents revised recommendations for assessing response in ET and PV provided by a working group established by ELN and International Working Group-Myeloproliferative Neoplasms Research and Treatment. New definitions of complete and partial remission incorporate clinical, hematological, and histological response assessments that include a standardized symptom assessment form and consider absence of disease progression and vascular events. We anticipate that these criteria will be adopted widely to facilitate the development of new and more effective therapies for ET and PV.

PubMed Disclaimer

References

    1. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829–4833. - PubMed
    1. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150(4):446–455. - PubMed
    1. Gisslinger H, Kralovics R, Gisslinger B, et al. AOP2014, a novel Peg-proline-interferon alpha-2b with improved pharmacokinetic properties, is safe and well tolerated and shows promising efficacy in patients with polycythemia vera (PV)[abstract]. Blood. 2012;120(21):175.
    1. Verstovsek S, Passamonti F, Rambaldi A, et al. Long-term efficacy and safety results from a Phase II study of ruxolitinib in patients with polycythemia vera [abstract]. Blood. 2012;120(21):804.
    1. Angona A, Bellosillo B, Alvarez-Larrán A, et al. Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide [abstract]. Blood. 2012;120(21):1738. - PubMed

Publication types

MeSH terms

Substances